<DOC>
	<DOCNO>NCT00520013</DOCNO>
	<brief_summary>The purpose research study evaluate patient newly diagnose advanced ovarian , fallopian tube , primary peritoneal cancer papillary serous clear cell mullerian tumor respond consolidation therapy Avastin erlotinib Avastin alone 1 year . These drug use treatment type cancer information study suggest agent may help treat cancer study .</brief_summary>
	<brief_title>Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin , Paclitaxel , Avastin ( CTA ) Induction Therapy Advanced Ovarian , Fallopian Tube , Primary Peritoneal Cancer &amp; Papillary Serous Clear Cell Mullerian Tumors</brief_title>
	<detailed_description>Objectives : Primary To examine progression free survival ( PFS ) Avastin Erlotinib ( AE ) Avastin ( A ) consolidation therapy . Secondary To examine toxicity two consolidative regimen AE vs. A . To assess response rate CTA . STATISTICAL DESIGN This study use randomize selection design . Both consolidation treatment arm deem experimental compare historical control [ McGuire WP et al . Cyclophosphamide cisplatin compare paclitaxel cisplatin patient stage III stage IV ovarian cancer . NEJM 1996 : 334:1-6 . PMID:7494563 ] . With 30 patient give arm 6 month follow-up , 80 % power detect 61.5 % increase median PFS 13 month 21 month assume 1-sided 10 % significance .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>18 year age old Histological diagnosis epithelial ovarian carcinoma , fallopian tube cancer , primary peritoneal carcinoma , papillary serous mullerian carcinoma Previous attempt surgical debulking Stage III IV Willing able undergo second look laparoscopy Performance status 01 ECOG scale Peripheral neuropathy &lt; grade 2 Life expectancy 6 month great Patients clinically significant cardiovascular disease outline protocol Neutrophil count &lt; 1,500/mm3 ; platelet count &lt; 100,000/m3 Alkaline phosphatase bilirubin &gt; 1.5 x ULN , SGOT &gt; 5 x ULN Calculated creatinine clearance &lt; 50ml/min Prior chemotherapy radiotherapy malignancy except treatment localize breast cancer great five year prior diagnosis No one cycle first line chemotherapy carboplatin paclitaxel Inadequate surgical cytoreduction interval cytoreductive surgery could materially improve prognosis Concurrent invasive malignancy Evidence bleed diathesis coagulopathy Evidence tumor involve major blood vessel prior CT scan Surgical wound fail close Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior day 0 Serious nonhealing wound , ulcer , bone fracture Prior treatment antiangiogenic agent Any active bleeding Active psychiatric disease neurologic symptom require treatment Presence central nervous system brain metastasis Proteinuria screen demonstrate criterion protocol Dementia significantly alter mental status would prohibit understanding and/or give informed consent Known hypersensitivity Cremophor EL component Avastin Active bacterial , viral , fungal infection Receiving investigational agent History gastrointestinal perforation Prior therapy target epidermal growth factor receptor Symptoms bowel obstruction Dependence TPN IV hydration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>